IBI343 plus chemo before surgery for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests whether adding the drug IBI343 to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. It is for those whose tumors have a specific protein called CLDN18.2 and have not spread to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that is borderline resectable (can possibly be removed with surgery).
- Your tumor has a protein called CLDN18.2 (a special marker found by a lab test).
- You have not had any prior treatment for this cancer, like surgery, chemo, or radiation.
- You are between 18 and 75 years old.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 1).
- You agree to use effective birth control during and for 6 months after treatment if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called IBI343 compared to a placebo (inactive substance) for people with advanced pancreatic cancer that has a specific protein (CLDN18.2) and has not responded to earlier treatments. The goal is to see if IBI343 can help slow the cancer's growth.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
This trial tests whether adding the drug ivonescimab to chemotherapy before surgery can help people with borderline resectable pancreatic cancer. The treatment is given for a short time to shrink the tumor and make surgery more likely to succeed.
This trial tests whether giving proton radiation and chemotherapy before surgery can shrink or control “borderline resectable” pancreatic cancer so it can be removed more effectively. It may help by improving treatment response while planning for surgery afterward.
This trial tests whether giving targeted radiation therapy first, followed by a combination chemotherapy (NALIRIFOX), is better than chemotherapy alone for people with pancreatic cancer that is borderline resectable. The goal is to see if the radiation helps shrink the tumor enough to make surgery possible.
This trial tests a combination of chemotherapy drugs (AG and FOLFIRINOX) with an immunotherapy drug (PD-L1 antibody) to shrink pancreatic tumors that are borderline resectable or locally advanced, making them removable by surgery. It's for people who haven't had any previous cancer treatment.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.